Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations

Journal of Heart and Lung Transplantation

Volumn 29, Issue 11, 2010, Pages 1210-1217

  Mathier, Michael A ^a   McDevitt, Susanne ^b   Saggar, Rajan ^c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNITED THERAPEUTICS CORPORATION   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

infusion site pain; pulmonary hypertension; subcutaneous; treprostinil; up titration

Indexed keywords

ALOE VERA EXTRACT; AMITRIPTYLINE; ARNICA MONTANA EXTRACT; BOSENTAN; CAPSAICIN; CETIRIZINE; CLOBETASOL PROPIONATE; DIPHENHYDRAMINE; DOXEPIN; FAMOTIDINE; FENTANYL; FEXOFENADINE; FLUTICASONE PROPIONATE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; HYDROCORTISONE; HYDROXYZINE EMBONATE; IBUPROFEN; ILOPROST; LIDOCAINE; LORATADINE; MAGNESIUM SULFATE; PARACETAMOL; PIMECROLIMUS; PROSTACYCLIN; RANITIDINE; SILDENAFIL; TRAMADOL; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG; UNIPROST;

ABDOMEN; ABSCESS DRAINAGE; ACUPRESSURE; ACUPUNCTURE; ANTIBIOTIC THERAPY; ARTICLE; BUTTOCK; CLINICAL EVALUATION; COLD TREATMENT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; HUMAN; INJECTION SITE ABSCESS; INJECTION SITE BLEEDING; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE WARMTH; MASSAGE; MONOTHERAPY; PATIENT SELECTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; TREATMENT OUTCOME; WALKING;

ANTIHYPERTENSIVE AGENTS; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; INFUSIONS, SUBCUTANEOUS; PAIN;

EID: 78049278260     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2010.06.013     Document Type: Article

References (47)

1. M. Gomberg-Maitland, and H. Olschewski Prostacyclin therapies for the treatment of pulmonary arterial hypertension Eur Respir J 31 2008 891 901
2. M. Humbert, O. Sitbon, and G. Simonneau Treatment of pulmonary arterial hypertension N Engl J Med 351 2004 1425 1436
3. R.J. Barst, L.J. Rubin, and W.A. Long A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension N Engl J Med 334 1996 296 302
4. M. Humbert, O. Sanchez, and M. Fartoukh Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study Eur Respir J 13 1999 1351 1356
5. M. Gomberg-Maitland, V.F. Tapson, and R.L. Benza Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension Am J Respir Crit Care Med 172 2005 1586 1589 (Pubitemid 43076550)
6. N. Skoro-Sajer, I.M. Lang, and E. Harja A clinical comparison of slow- and rapid-escalation treprostinil dosing regimens in patients with pulmonary hypertension Clin Pharmacokinet 47 2008 611 618
7. R.J. Barst, N. Galie, and R. Naeije Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Eur Respir J 28 2006 1195 1203 (Pubitemid 44883856)
8. I. Lang, M. Gomez-Sanchez, and M. Kneussl Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension Chest 129 2006 1636 1643
9. V.V. McLaughlin, S.P. Gaine, and R.J. Barst Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension J Cardiovasc Pharmacol 41 2003 293 299
10. R.J. Oudiz, R.J. Schilz, and R.J. Barst Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease Chest 126 2004 420 427
11. M. Rubenfire, V.V. McLaughlin, and R.P. Allen Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial Chest 132 2007 757 763
12. G. Simonneau, R.J. Barst, and N. Galie Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial Am J Respir Crit Care Med 165 2002 800 804
13. O. Sitbon, A. Manes, and X. Jais Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension J Cardiovasc Pharmacol 49 2007 1 5
14. N. Skoro-Sajer, D. Bonderman, and F. Wiesbauer Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension J Thromb Haemost 5 2007 483 489 (Pubitemid 46680679)
15. V.F. Tapson, M. Gomberg-Maitland, and V.V. McLaughlin Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial Chest 129 2006 683 688
16. J.-L. Vachiry, N. Hill, and D. Zwicke Transitioning from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension Chest 121 2002 1561 1565
17. J.P. Feldman, M. Chakinala, and F. Torres Treprostinil sodium improves exercise capacity when added to existing oral pulmonary arterial hypertension therapy Chest 132 suppl 2007 474S 475
18. M. Wade, F.J. Baker, and R. Roscigno Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion J Clin Pharmacol 44 2004 83 88 (Pubitemid 38005097)
19. M. Wade, F.J. Baker, and R. Roscigno Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion J Clin Pharmacol 44 2004 503 509 (Pubitemid 38509719)
20. C.S. McSwain, R. Benza, and S. Shapiro Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion J Clin Pharmacol 48 2008 19 25
21. K. Laliberte, C. Arneson, and R. Jeffs Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers J Cardiovasc Pharmacol 44 2004 209 214
22. V.V. McLaughlin, A. Shillington, and S. Rich Survival in primary pulmonary hypertension: the impact of epoprostenol therapy Circulation 106 2002 1477 1482
23. O. Sitbon, M. Humbert, and H. Nunes Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival J Am Coll Cardiol 40 2002 780 788
24. Sadushi-Kolici R, Bonderman D, Skoro-Sajer N, et al. Long-term outcome with subcutaneous treprostinil sodium in pulmonary hypertension: a 10-year single-center study. Poster presented at the American Thoracic Society International Conference, May 2009, San Diego, CA.
25. Frantz R, McGoon M, Waxman AB, et al. Multicenter experience with the transition to IV/SC treprostinil from inhaled iloprost in pulmonary arterial hypertension. Poster presented at the Pulmonary Hypertension Association 8th International PH Conference and Scientific Sessions, June 2008, Houston, TX.
26. Remodulin [package insert] 2010 United Therapeutics Corp Research Triangle Park, NC
27. Soto FJ, Derksen T, Janusz J, et al. Single center experience with rapid dose escalation of sub-cutaneous (SQ) treprostinil for the treatment of pulmonary arterial hypertension. Poster presented at the Pulmonary Hypertension Association 7th International PH Conference, June 2006, Minneapolis, MN.
28. F.J. Soto Safety and tolerance of a rapid 35 day in-hospital up-titration protocol of subcutaneous (SQ) treprostinil in patients with severe pulmonary arterial hypertension (PAH) [abstract] Chest 132 suppl 2007 634S
29. Soto FJ, Girotra S, Presberg K. Subcutaneous (SC) treprostinil for severe pulmonary arterial hypertension (PAH): hemodynamic and clinical outcomes in naive, add-on and transition patients. Poster presented at the American Thoracic Society 2008 International Conference, May 2008, Toronto, ON, Canada.
30. F.J. Soto, P. Jain, and J. Kleczka Clinical and hemodynamic impact of subcutaneous (SQ) treprostinil (Remodulin) in the management of pulmonary arterial hypertension (PAH): single-center experience [abstract] Chest 130 suppl 2006 120S
31. B. Raychaudhuri, A. Malur, and T.L. Bonfield The prostacyclin analogue treprostinil blocks NFkappaB nuclear translocation in human alveolar macrophages J Biol Chem 277 2002 33344 33348
32. 2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells J Immunol 178 2007 702 710 (Pubitemid 46095142)
33. T.A. Samad, A. Sapirstein, and C.J. Woolf Prostanoids and pain: unraveling mechanisms and revealing therapeutic targets Trends Mol Med 8 2002 390 396
34. S.L. Tilley, T.M. Coffman, and B.H. Koller Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes J Clin Invest 108 2001 15 23
35. Data on file, United Therapeutics Corporation.
36. L.K. Ashby, K. Hague, and L. Latham Protocol for reduction of site pain in the administration of treprostinil Chest 126 4 suppl 2004 882S
37. F.J. Soto, S. Girotra, and H. Cain Longer time interval between infusion site changes for subcutaneous (SQ) treprostinil (Remodulin) in patients with pulmonary hypertension (PH): tolerance and safety Am J Respir Crit Care Med 175 2007 A401
38. K.M. Chin, and L.J. Rubin Pulmonary arterial hypertension J Am Coll Cardiol 51 2008 1527 1538
39. J. Hiremath, S. Thanikachalam, and K. Parikh Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial J Heart Lung Transplant 29 2010 137 149
40. Ventavis [package insert] 2009 Actelion Pharmaceuticals San Francisco, CA
41. H. Olschewski, B. Rohde, and J. Behr Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension Chest 124 2003 1294 1304
42. H. Olschewski, G. Simonneau, and N. Gali Inhaled iloprost for severe pulmonary hypertension N Engl J Med 347 2002 322 329 (Pubitemid 34815354)
43. R. Voswinckel, B. Enke, and F. Reichenberger Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies J Am Coll Cardiol 48 2006 1672 1681
44. R.N. Channick, H. Olschewski, and W. Seeger Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension J Am Coll Cardiol 48 2006 1433 1437
45. R. Voswinckel, F. Reichenberger, and B. Enke Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension Pulm Pharmacol Ther 21 2008 824 832
46. N. Skoro-Sajer, I. Lang, and R. Naeije Treprostinil for pulmonary hypertension Vasc Health Risk Manag 4 2008 507 513
47. Tyvaso [package insert] 2009 United Therapeutics Corporation Research Triangle Park, NC